𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Disease-specific biomarker discovery by aptamers

✍ Scribed by Henning Ulrich; Carsten Wrenger

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
298 KB
Volume
75A
Category
Article
ISSN
0196-4763

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The role of electrophoresis in disease b
The role of electrophoresis in disease biomarker discovery
✍ Haleem J. Issaq; Timothy D. Veenstra πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 442 KB

## Abstract There has been increased activity in the last few years in the search for disease markers using fractionation of complex biological fluids combined with MS. While electrophoretic and chromatographic separations have played a major role in this endeavor, this manuscript is limited to a r

Recognition of biomarkers and cell-speci
Recognition of biomarkers and cell-specific molecular signatures: Aptamers as capture agents
✍ Arthur A. Nery; Carsten Wrenger; Henning Ulrich πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 967 KB

## Abstract RNA and DNA aptamers developed by systematic evolution of ligands by exponential enrichment (SELEX) have turned into important tools in diagnostics, research, and therapeutics. Unlike antibodies, high‐affinity and specific aptamers identified through an __in vitro__ selection process ca

New proteomic approaches for biomarker d
New proteomic approaches for biomarker discovery in inflammatory bowel disease
✍ Giulia Roda; Alessandra Caponi; Marco Benevento; Paolo Nanni; Laura Mezzanotte; πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 101 KB πŸ‘ 1 views

There is an increasing interest in the discovery of new inflammatory bowel disease (IBD) biomarkers able to predict the future patterns of disease and to help in diagnosis, treatment, and prognosis. A biomarker is a substance that can be measured biologically and is associated with an increased risk

Serum proteomics and biomarker discovery
Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease
✍ Lauren N. Bell; Janice L. Theodorakis; Raj Vuppalanchi; Romil Saxena; Kerry G. B πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 361 KB πŸ‘ 2 views

Nonalcoholic fatty liver disease (NAFLD), ranging from relatively benign simple steatosis to progressive nonalcoholic steatohepatitis (NASH) and fibrosis, is an increasingly common chronic liver disease. Liver biopsy is currently the only reliable tool for staging the subtypes of NAFLD; therefore, n